Author Archives: Jan Paschal

HawkEye 360 (HAWK) priced its IPO at $26.00 – the top of its $24.00-to-$26.00 range – and sold 16 million shares – the number in the prospectus – to raise $416 million on Wednesday night, May 6, 2026. The U.S. defense contractor’s stock soared in its NYSE debut – opening above $33.00. HawkEye 360 (HAWK) was […]

Rare Earths Americas, Inc. (REA) upsized its small IPO by 20 percent at pricing on Tuesday night, May 5, 2026 – increasing the number of shares to 3.33 million shares – up from 2.78 million in the prospectus – and pricing its IPO at $19.00 – the top of its range – to raise $63.33 […]

Cerebras Systems (CRBS Proposed) pulled back the curtain on its IPO playbook early today with the launch of its $3.36 billion IPO to price next week. The Sunnyvale, California-based Cerebras, an AI-focused semiconductor company, is offering 28 million shares at a price range of $115.00 to $125.00 to raise $3.36 billion, if priced at the […]

HawkEye 360 (HAWK Proposed), a satellite company that runs a satellite signal-processing platform,  is the headliner for the first week of  May 2026. With estimated IPO proceeds of $400 million, HawkEye 360 is the single largest deal this week. HawkEye 360 represents about 52.12 percent of the proceeds – in U.S. dollar volume – for […]

Seaport Therapeutics (SPTX), a Boston-based biotech developing drugs to treat major depression, increased its IPO’s size at pricing – to 14.16 million shares – up from 11.8 million in the prospectus – and priced its IPO at $18.00 – the top of its range – to raise $254.88 million on  Thursday night, April 30, 2026. Shares […]

Twice is nice. Hemab Therapeutics (COAG) upsized its IPO again at pricing last night – increasing its size to 16.75 million shares – up from 15 million shares earlier in the day – and priced its IPO at $18.00 – the top of its range – to raise $301.5 million on Thursday night, April 30, […]

Avalyn Pharma (AVLN), a clinical biotech pioneering inhaled treatments for rare respiratory disorders, priced its upsized IPO of 16.67 million shares at $18.00 – the top of its $16.00-to-$18.00 price range – and raised $300.06 million on Wednesday night, April 29, 2026. Shares of Avalyn Pharma (AVLN) surged in their NASDAQ debut to open at […]

Bill Ackman’s Pershing Square USA Ltd. (PSUS), a closed-end fund, and Pershing Square Inc. (PS), the management company for Ackman’s funds, raised about $5 billion through a combined IPO and private placement on Tuesday night, April 28, 2026, the company said. The IPO was priced at $50.00 per share. The private placement alone raised about […]

Biotechs are back in play. Two IPOs – Hemab Therapeutics (COAG Proposed) and Seaport Therapeutics (SPTX Proposed)   – launched early Monday to price on Thursday night, April 30, and trade Friday, May 1. Those deals joined Avalyn Pharma (AVLN Proposed) – a pulmonary fibrosis-focused biotech IPO that launched last week. All told, these three biotech […]

X-Energy (XE) upsized its IPO at pricing to 44.25 million shares – up from 42.86 million in the prospectus – and priced the deal at $23.00 – $4.00 above the top of its $16.00-to-$19.00 range – to raise about $1.02 billion on Thursday night, April 23, 2026. Shares of X-Energy (XE) jumped $7.11 from their […]